Aktiesnakken — Januar 2010
-
på den korte bane bliver det EGFR data der driver den. Men det kan jo gå galt. Og så skal den ned. Så lad os nu sige at EGFR data er positiv
-
så stiger genmab, men stiger den på samme dag
-
15% så kan du købe og stadig have en kæmpe upside uden risiko
-
I min pension har jeg meget kedelige valueaktier
-
jo men desværre også store tab på countrywide, bank of america
-
ja c20 steg 60% og genmab faldt 60%, så det var IKKE den rigtige aktier i 2009
-
håber jeg også. Jeg pliiiinger af og hopper i sygesengen -
i lige måde
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind